<DOC>
	<DOCNO>NCT00003413</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy plus peripheral stem cell transplantation treat patient stage III stage IV ovarian epithelial cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Treating Patients With Stage III Stage IV Ovarian Epithelial Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate complete response rate , event free survival , overall survival patient recently diagnose stage III IV ovarian epithelial cancer receive carmustine plus melphalan follow consolidation therapy undergone surgical debulking . II . Evaluate therapy relate mortality associate autotransplant consolidation therapy patient . III . Evaluate quality life patient population . OUTLINE : Patients stratify stage ( III v IV ) volume residual disease ( le 3 cm v least 3 cm ) . Approximately 10-15 day surgery , patient receive filgrastim ( G-CSF ) subcutaneously daily peripheral blood stem cell ( PBSC ) collection complete . Patients receive carmustine IV 2 hour day -2 melphalan IV 20 minute day -1 . Peripheral blood stem cell infuse 24 hour melphalan day 0 . Patients receive G-CSF subcutaneously begin day 6 continue granulocyte recover . Three month PBSC infusion , patient receive consolidation therapy paclitaxel IV 6 hour day 2 cisplatin IV 24 hour day 3 . Consolidation treatment repeat every 3 month total 4 course . Quality life questionnaire complete prior PBSC transplant , discharge transplant , consolidation treatment , 3 month last consolidation course . Patients follow least every 3 month first 2 year , every 6 month thereafter . PROJECTED ACCRUAL : An estimated 32 patient accrue study 3-4 year .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage III IV ovarian epithelial cancer undergone surgical debulking Stage III patient must great 1 cm residual mass surgery Must 1 course platinum base chemotherapy No CNS disease PATIENT CHARACTERISTICS : Age : 18 70 Performance status : SWOG 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 1.5 mg/dL Transaminases great 4 time upper limit normal No active chronic hepatitis liver cirrhosis Renal : Creatinine great 3.0 mg/dL Cardiovascular : LVEF least 50 % Pulmonary : FVC , FEV1 , correct DLCO least 50 % predict If unable complete pulmonary function test due pain related recent surgery , patient must high resolution CT scan chest acceptable arterial blood gas ( PO2 least 70 ) Other : HIV negative No active infection require intravenous antibiotic Not pregnant nursing Effective contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
</DOC>